Difference between revisions of "KRAS mutation"
Jump to navigation
Jump to search
| Line 20: | Line 20: | ||
==Microscopic== | ==Microscopic== | ||
Features: | Features: | ||
*Typically [[mucinous carcinoma]] | *In [[lung adenocarcinoma]]: | ||
*Associated with tumour-infiltrating leukocytes | **Typically [[mucinous carcinoma]].<ref name=pmid25029118>{{Cite journal | last1 = Kadota | first1 = K. | last2 = Yeh | first2 = YC. | last3 = D'Angelo | first3 = SP. | last4 = Moreira | first4 = AL. | last5 = Kuk | first5 = D. | last6 = Sima | first6 = CS. | last7 = Riely | first7 = GJ. | last8 = Arcila | first8 = ME. | last9 = Kris | first9 = MG. | title = Associations between mutations and histologic patterns of mucin in lung adenocarcinoma: invasive mucinous pattern and extracellular mucin are associated with KRAS mutation. | journal = Am J Surg Pathol | volume = 38 | issue = 8 | pages = 1118-27 | month = Aug | year = 2014 | doi = 10.1097/PAS.0000000000000246 | PMID = 25029118 }}</ref> | ||
**Associated with tumour-infiltrating leukocytes.<ref name=pmid23619604>{{Cite journal | last1 = Rekhtman | first1 = N. | last2 = Ang | first2 = DC. | last3 = Riely | first3 = GJ. | last4 = Ladanyi | first4 = M. | last5 = Moreira | first5 = AL. | title = KRAS mutations are associated with solid growth pattern and tumor-infiltrating leukocytes in lung adenocarcinoma. | journal = Mod Pathol | volume = 26 | issue = 10 | pages = 1307-19 | month = Oct | year = 2013 | doi = 10.1038/modpathol.2013.74 | PMID = 23619604 }}</ref> | |||
*In [[colorectal carcinoma]]: | *In [[colorectal carcinoma]]: | ||
**No correlation in one study.<ref name=pmid23157826 >{{Cite journal | last1 = Gao | first1 = J. | last2 = Zhang | first2 = J. | last3 = Lu | first3 = T. | last4 = Li | first4 = XY. | last5 = Jia | first5 = N. | last6 = Liang | first6 = ZY. | title = [Correlation between KRAS mutations and clinicopathologic features in colorectal carcinomas]. | journal = Zhonghua Bing Li Xue Za Zhi | volume = 41 | issue = 9 | pages = 595-8 | month = Sep | year = 2012 | doi = | PMID = 23157826 }}</ref> | **No correlation in one study.<ref name=pmid23157826 >{{Cite journal | last1 = Gao | first1 = J. | last2 = Zhang | first2 = J. | last3 = Lu | first3 = T. | last4 = Li | first4 = XY. | last5 = Jia | first5 = N. | last6 = Liang | first6 = ZY. | title = [Correlation between KRAS mutations and clinicopathologic features in colorectal carcinomas]. | journal = Zhonghua Bing Li Xue Za Zhi | volume = 41 | issue = 9 | pages = 595-8 | month = Sep | year = 2012 | doi = | PMID = 23157826 }}</ref> | ||
Revision as of 18:25, 4 November 2016
KRAS mutation is a re-occuring theme in molecular pathology. KRAS is an oncogene.[1]
General
Seen in:
Not seen in the context of:
- ALK rearrangements in non-small cell lung cancer.[3]
- Almost mutually exclusive to BRAF (V600E) in colon cancer.[4]
Implication
In the context of colorectal carcinoma:[5][6]
- Patient must have wild type KRAS to get drugs; KRAS mutation predicts resistance to cetuximab (Erbitux) and panitumumab (Vectibix).
Gross
In colorectal carcinoma:
- Typically right sided lesions.[4]
Microscopic
Features:
- In lung adenocarcinoma:
- Typically mucinous carcinoma.[7]
- Associated with tumour-infiltrating leukocytes.[8]
- In colorectal carcinoma:
See also
References
- ↑ Online 'Mendelian Inheritance in Man' (OMIM) 190070
- ↑ Monzon, FA.; Ogino, S.; Hammond, ME.; Halling, KC.; Bloom, KJ.; Nikiforova, MN. (Oct 2009). "The role of KRAS mutation testing in the management of patients with metastatic colorectal cancer.". Arch Pathol Lab Med 133 (10): 1600-6. doi:10.1043/1543-2165-133.10.1600. PMID 19792050.
- ↑ Gainor, JF.; Varghese, AM.; Ou, SH.; Kabraji, S.; Awad, MM.; Katayama, R.; Pawlak, A.; Mino-Kenudson, M. et al. (Aug 2013). "ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer.". Clin Cancer Res 19 (15): 4273-81. doi:10.1158/1078-0432.CCR-13-0318. PMID 23729361.
- ↑ 4.0 4.1 4.2 Gonsalves, WI.; Mahoney, MR.; Sargent, DJ.; Nelson, GD.; Alberts, SR.; Sinicrope, FA.; Goldberg, RM.; Limburg, PJ. et al. (Jul 2014). "Patient and tumor characteristics and BRAF and KRAS mutations in colon cancer, NCCTG/Alliance N0147.". J Natl Cancer Inst 106 (7). doi:10.1093/jnci/dju106. PMID 24925349.
- ↑ Dunn EF, Iida M, Myers RA, et al. (October 2010). "Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab". Oncogene. doi:10.1038/onc.2010.430. PMID 20956938.
- ↑ Di Nicolantonio F, Martini M, Molinari F, et al. (December 2008). "Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer". J. Clin. Oncol. 26 (35): 5705–12. doi:10.1200/JCO.2008.18.0786. PMID 19001320.
- ↑ Kadota, K.; Yeh, YC.; D'Angelo, SP.; Moreira, AL.; Kuk, D.; Sima, CS.; Riely, GJ.; Arcila, ME. et al. (Aug 2014). "Associations between mutations and histologic patterns of mucin in lung adenocarcinoma: invasive mucinous pattern and extracellular mucin are associated with KRAS mutation.". Am J Surg Pathol 38 (8): 1118-27. doi:10.1097/PAS.0000000000000246. PMID 25029118.
- ↑ Rekhtman, N.; Ang, DC.; Riely, GJ.; Ladanyi, M.; Moreira, AL. (Oct 2013). "KRAS mutations are associated with solid growth pattern and tumor-infiltrating leukocytes in lung adenocarcinoma.". Mod Pathol 26 (10): 1307-19. doi:10.1038/modpathol.2013.74. PMID 23619604.
- ↑ Gao, J.; Zhang, J.; Lu, T.; Li, XY.; Jia, N.; Liang, ZY. (Sep 2012). "[Correlation between KRAS mutations and clinicopathologic features in colorectal carcinomas].". Zhonghua Bing Li Xue Za Zhi 41 (9): 595-8. PMID 23157826.